ArticleHPB : the official journal of the International Hepato Pancreato Biliary Association2011
Multicentre study of liver metastases from colorectal cancer in pathological livers.
Article in HPB : the official journal of the International Hepato Pancreato Biliary Association, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Focal Liver Lesions other than Hepatocellular Carcinoma in Cirrhosis: Diagnostic Challenges.Journal of translational internal medicine · 2022Article
- Higher titer hepatitis B core antibody predicts a higher risk of liver metastases and worse survival in patients with colorectal cancer.World journal of surgical oncology · 2021Article
- Impact of tumor-parenchyma biomechanics on liver metastatic progression: a multi-model approach.Scientific reports · 2021Article
- Preoperative selection of patients with colorectal cancer liver metastasis for hepatic resection.World journal of gastroenterology · 2016Review
- Thermal Radiofrequency Ablation as an Adjuvant Therapy for Patients With Colorectal Liver Metastasis.Oncology research · 2016Article
- Metastatic colorectal cancer in a cirrhotic liver with synchronous hepatocellular carcinoma.Annals of translational medicine · 2015Article
- Peroxisome proliferator-activated receptor-α staining is associated with worse outcome in colorectal liver metastases.Molecular and clinical oncology · 2015Article
- [Assessment of resectability of colorectal liver metastases and extended resection].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesResection of colorectal cancer (CRC) liver metastases (LM) in pathological liver (PL) patients (with cirrhosis or hepatopathy) is extremely rare. The aim of this study was to perform a multicentre, retrospective analysis of epidemiology, surgical techniques and outcomes in patients with PL who underwent hepatic resection for CRC-LM.
methodsA retrospective, multicentre questionnaire was distributed to 15 hepatopancreatobiliary surgical units.
resultsOnly six of 15 (40%) HPB units reported any experience in the surgical resection of CRC-LM in patients with PL. Of the 20 patients identified, 10 had underlying cirrhosis and 10 had chronic hepatopathy. Their median age was 66 years (range: 49-81 years). Thirteen patients were male. Liver dysfunction was known preoperatively in 18 patients. All patients had Child-Pugh class A disease. Six patients had synchronous disease. There were a total of 38 lesions among the 20 patients, distributed at a median of one lesion per patient (range: 1-4 lesions). The median size of the lesions was 3.0 cm (range: 1.5-9.0 cm). Preoperative median carcinoembryonic antigen (CEA) was 32.3 ng/ml (range: 1-184 ng/ml). The surgical procedures performed included: sub-segmentectomy (n= 12); left lateral sectionectomy (n= 6); segmentectomy (n= 4); radiofrequency ablation (n= 3), and exploratory laparotomy (n= 4). Morbidity occurred in four patients (Clavien grades I [n= 1], II [n= 2] and IVa [n= 1]). Mortality was nil. An R0 resection margin was achieved in 15 of 16 patients. Twelve patients did not receive chemotherapy. In resected patients, 10 presented with relapse. The median disease-free and overall survival periods were 12.2 and 22.3 months, respectively.
conclusionsWhen feasible, liver resection is the best option for CRC-LM in PL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.